26/6/2025–|Last update: 14:21 (Mecca time)
A new study showed that Orforglipron, which can be taken orally tablets, has the effectiveness of the weekly adzmopic syringe in stimulating weight loss and lowering blood sugar.
The researchers presented the results of their studies at the annual meeting of the American Diabetes Association held between 20 and 23 June, in the city of Chicago, Illinois, in the United States, and wrote about the New York Times.
Some estimates indicate that one out of every 8 adults in the United States has already taken a drug like The waves or BeautyAnd researchers believe that a number of people will use many people who will use weight loss medications that do not require our weekly right, for this reason, doctors and investors feel great enthusiastically towards Orforgloberone.
Mimic Orforgloberone Like Osmbek and other medicines available in the market- Hormonna regulates blood sugar and curbs appetite.
The researchers, who followed more than 500 patients with type 2 diabetes, indicated that those who took the highest dose on average about 16 lbs (7.25 kilograms) after 9 months, and about two -thirds of the people who took the drug witnessed a decrease in blood sugar levels.
ELI Lilly, the pharmaceutical pharmaceutical company, will publish data from additional studies on Orforgleberone in people who are obese later this year.
The company will seek to obtain the approval of the regulatory authorities for the drug first as a treatment for obesity, then later to treat type 2 diabetes. The company did not announce the cost of Orforgleberone, but its production in large quantities is generally cheaper than the injection production.
New experimental drugs
Orforgloberone is only one of more than 12 experimental drugs, the researchers will share its data at the conference. Some of these drugs are still in the initial experiment, but others may be put on the market next year.
These drugs include a treatment that may lead to a greater weight loss than those who use current drugs, which ranges between 15% and 20%. It may also be easier to eat weekly injection, and help people lose weight without losing many muscles.
Researchers have provided data on other drugs in early stages that may be more appropriate than weekly injection, and included Maritide, a drug that is injected from the production of Amgen Biotropic Company, and patients can take it once a month.
Medicines developers seek to find a solution to muscle loss that occurs when using weight loss medications. Patients who lose fat also tend to lose muscles, and this may be particularly dangerous for the elderly because it makes them more vulnerable to fall and can exacerbate osteoporosis.
One of the experimental drugs collects the substance in Ozmbek and a compound that blocks the receptors that regulate the mass of structural muscles and fats.
Many other drugs mimic the amylan hormone, which has shown on rodents its ability to maintain some meager muscle tissue, despite the need for more data on humans.
Some researchers are still skeptical that any drug can lead to a great weight loss without sacrificing at least some muscles.